JENNIFER: THERE HAVE BEEN BIG DEVELOPMENTS WITH THE COVID VACCINE IN THE PAST WEEK. JOINING US THIS MORNING TO BREAK IT DOWN, DR. CHRISTOPHER THOMPSON FROM LOYOLA UNIVERSITY. THANKS FOR JOINING US AGAIN. >> THANKS FOR HAVING ME. JENNIFER: PFIZER GOT THE FULL FDA APPROVAL. EXPLAIN THE FOLKS THE DIFFERENCE BETWEEN EMERGENCY USE AND THE FULL APPROVAL. >> RIGHT. SO EMERGENCY USE IS JUST WTHA THE NAME SAYS. WE'RE IN AN EMERGENCY. WE NEED SOMETHG,IN AND SO IS THIS GOOD ENOUGH TO WORK. FULL APPROVAL MEANS THAT WE'VE HAD A LOT MORE SAFETY DATA AND A LOT MORE EFFICACY DAAT THAT ALL SHOW POSITIVE SIGNS FOR THIS. SO THE FULL APPROVAL REALL Y MEANS THIS IS A VERY, VERY SAFE VACCINE AND A VERY EFFECTIVE VACCINE. JENNIFER: ANY IDEA WHATS THI MIGHT MEANS FOR MANDATES MOVING FORWARD. ALREADY, MANY BUSINESSES AND BIG COMPANIES ARE REQUIRING VACCINES. >> COMPANS,IE BUSINESSES CAN REQUIRE VACCINATION, EVEN IF IT'S UNDER EMERGENCY E.US WHAT I'M HOPING IS THAT THIS FULL APPROVAL GIVES PEOPLE WHO ARE STILL A LITTLE BIT ON THE FENCE ABOUT WHETHER OR NOT TO GET THE VACCINE WILL GIVE THEM THE NUDGE IN THE RIGHT DIRECTION. THE KAISER FAMILY FOUNDATION DID A STUDY THAT SUGGESTED THAT PEOPLE MIGHT ACTUALLY GO GET THE VACCIN OENCE IT IS FULLY APPROVED. I'M HOPEFUL THAT THAT HAPPENS. >> WE'VE BEEN TALKING ABOUT BOOSTERS. THEY'RE RECOMMENDED SPECIFICALLY FOR PEOPLE WHO ARE IMMUNE COMPROMISED. WHEN DO YOU SEE THIS BECOMING AVAILABLTOE BASICALLY EVERYONE? SO A SLIGHT DIFFERENCE. FOR PEOPLE IMMUNE COMPROMISED, WE'RE RECOMMENDING A THIRD DOSE. THAT GETS THEM UP TO THE LEVEL OF PROTECTION THAT PEOPLE WHO ARE NOT IMMUNE COMPROMISED ALREADY HAVE. THE BOOSTER IS TO BOOST THE RESPONSE THAT MAY HAVE WAYNED OVER TIME. WE'RE SEEING IT IN THE PEOPLE OVER 60 IN ISRAEL AND IN THE U.S. WE'RE SEEING RECOMMENDATIONS FOR PEOPLE PEOPLE OVERHE T AGE OF 60. CURRENT DATA SAYS THAT, YOU KNOW, OUR PROTECTNIO DROPPED FROM ABOUT 90% TO ABOUT 80% OVER A COUPLE OF MONTHS. SO STILL REALLY, REALLY GOOD PROTECTION AGAINST DELTA X GREAT PROTECTION AGAINST SEVERE DISEASE AND DEATH. SO THERE'S NO REAL RUSH TO RUN OUT ANDET GT RIGHT NOW. BUT I THINK PEOPLE OVER THE AGE OF 60 WHO ARE MOST WORRISOME POPULATION AS FAR AS GETTING SEVERE DISEASE SHOULD START CONSIDERING THAT. JENNIFER: WHEN IT COMES TO GETTING E THBOOSTER, DO YOU HAVE TO GET THE SAME BOOSTER AS THE ORIGINAL FIRST TWO SHOTS YOU RECEIVED? >> YEAH, SO, THERE REALLY NOT GOOD DATA ABOUTHE T BOOSTER OVERALL. I'M HESITANT TO SAY WHAT THE DATA SAYS, WHICH IS MY M.O. FOR OUR INTERVIEWS. SO I DON'T THINK SO. THE LIMITED DATA I'VE SEEN SUGGESTS THAT, YOU KNOW, IF YOU GET THE OTHER COMPANY'S MRNA VACCINE, IT SHOULD STILL BE EFFECTIVE. BUT THE DATA IS REALLY, REALLY LIMITED. YOU'RE PROBABLY BETTER OFF GETTING THE SAME ONE THAT YOU HAD, AND I THINK THAT'S WHAT MOST PEOPLERE A RECOMMENDING. >> AND THEN FOR THOSE WHO ARE STARTING TO GET THE BOOSTER, IS THERE DATA THAT TY'HERE STARTING TO SEE THE SIDE EFFECTS THAT THEYOT G FROM THE OTHER SHOTS. >> THERE'S LIMITED DATA ABOUT THAT. I CAN'T COMMENT. JENNIFER: WHAT ABOUT THIS MONOCLONAL ANTIBODY VACCINE THEY'RE TALKING ABOUT THATE W RAN A STORY ON EARLIER THIS MORNING THAT'S SUPPOSE TBEO D EFFECTIVE AGAINST DELTA? >> YEAH, SO MONLONALOC ANTIBODIES ARE A LAB VERSION OF WHAT OUR BODY MAKES TO FIGHTFF O INFECTION. MONOCLONAL MEANS THAT IT ATTACKS ONE, MONO, ATTACKS ONE SITE ON ETH VIRUS. SO IT'S NOT A VACCINE. IT'S A TREATMENT WE'RE SEEING. AND IT SEEMSO TBE EFFECTIVE AGAINST THIS DELTA VARIANT. AND IT STARTS TO WIPE OUT THE INFECTION AS SOON AS YOU GET THE INFUSION. SO IT'S A REALL GYREAT STEP FORWARD IN TREATING INFECTION WITH DELTA, BUT YOU'RE STILL BETTER OFF GETTING THE VACCINE TO PREVENT EVER GETTING IT IN THE FIT RSPLACE. JENNIFER: DR. THOMPSON, ALWAYS A PLEASURE TO HAVE YOU ON. THANK YOU FOR YOU